Mediclinic International plc Directorate Change (3916H)
November 15 2018 - 2:01AM
UK Regulatory
TIDMMDC
RNS Number : 3916H
Mediclinic International plc
15 November 2018
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company" or the "Group")
15 November 2018
DIRECTORATE CHANGE
The Company announces that on 14 November 2018, Mr Desmond
Smith, the Company's Senior Independent Director, informed the
Board of his intention to retire as a director of the Company at
the conclusion of the Company's Annual General Meeting ("AGM")
scheduled for 24 July 2019 and not seek re-election at the AGM. Mr
Smith will also step down from all Board committees at that
time.
Mr Alan Grieve will succeed Mr Smith as Senior Independent
Director of the Company and as Chairman of the Audit and Risk
Committee, to be effective from the date of Mr Smith's resignation
in 2019.
Further changes to the constitution of the Company's committees
will be made and announced in due course.
Mediclinic's chairman, Dr Edwin Hertzog commented:
"On behalf of my colleagues on the Board, I would like to thank
Desmond for his commitment and valued contributions to the Board
and the Group over many years."
This announcement is made in accordance with the requirement of
LR 9.6.11.
About Mediclinic International plc
Mediclinic is an international private healthcare services group
with operating divisions in Switzerland, Southern Africa (South
Africa and Namibia) and the United Arab Emirates. Its core purpose
is to enhance the quality of life of patients by providing acute
care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire
Healthcare Group plc, an LSE-listed and UK-based private healthcare
group.
Mediclinic comprises 76 hospitals and 30 clinics. Hirslanden
operates 18 private hospitals and 4 clinics in Switzerland with
more than 1 900 inpatient beds; Mediclinic Southern Africa operates
48 hospitals and 4 day clinics throughout South Africa and 3
hospitals in Namibia with more than 8 100 inpatient beds in total;
and Mediclinic Middle East operates 7 hospitals and 22 clinics with
more than 900 inpatient beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE
in the United Kingdom, with secondary listings on the JSE in South
Africa and the NSX in Namibia.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International
plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank
Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAGGGMCGUPRGQC
(END) Dow Jones Newswires
November 15, 2018 02:01 ET (07:01 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2023 to Apr 2024